The duration of infectiousness of individuals infected with SARS-CoV-2 - 08/12/20
, Susan Spillane a, 1, Laura Comber a, Karen Cardwell a, b, Patricia Harrington a, Jeff Connell c, Conor Teljeur a, Natasha Broderick a, Cillian F. de Gascun c, Susan M. Smith b, Máirín Ryan a, d, 2, Michelle O'Neill a, 2
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | 15 studies were included - 13 SARS-CoV-2 culture and 2 contact tracing studies. |
• | Mild-to-moderate COVID-19 patients highly unlikely to be infectious after day 10. |
• | Immunocompromised and severe-to-critical patients may be infectious for >10 days. |
• | This evidence may be used to inform duration of isolation guidance. |
Summary |
Objectives |
To summarise the evidence on the duration of infectiousness of individuals in whom SARS-CoV-2 ribonucleic acid is detected.
Methods |
A rapid review was undertaken in PubMed, Europe PubMed Central and EMBASE from 1 January 2020 to 26 August 2020.
Results |
We identified 15 relevant studies, including 13 virus culture and 2 contact tracing studies. For 5 virus culture studies, the last day on which SARS-CoV-2 was isolated occurred within 10 days of symptom onset. For another 5 studies, SARS-CoV-2 was isolated beyond day 10 for approximately 3% of included patients. The remaining 3 virus culture studies included patients with severe or critical disease; SARS-CoV-2 was isolated up to day 32 in one study. Two studies identified immunocompromised patients from whom SARS-CoV-2 was isolated for up to 20 days. Both contact tracing studies, when close contacts were first exposed greater than 5 days after symptom onset in the index case, found no evidence of laboratory-confirmed onward transmission of SARS-CoV-2.
Conclusion |
COVID-19 patients with mild-to-moderate illness are highly unlikely to be infectious beyond 10 days of symptoms. However, evidence from a limited number of studies indicates that patients with severe-to-critical illness or who are immunocompromised, may shed infectious virus for longer.
Le texte complet de cet article est disponible en PDF.Keywords : SARS-CoV-2, COVID-19, Isolation, Infectiousness, Review, Coronavirus, RNA, Virus culture, Contact tracing
Plan
Vol 81 - N° 6
P. 847-856 - décembre 2020 Retour au numéro
Article précédent
- Editorial Board
- Developing new therapeutic approaches for treating infections caused by multi-drug resistant Acinetobacter baumannii : Acinetobacter baumannii therapeutics
- Peter Gallagher, Stephen Baker
Bienvenue sur EM-consulte, la référence des professionnels de santé.